Scientists have reported promising long-term results from a study combining a personalized mRNA vaccine with a leading immunotherapy drug to help prevent melanoma from returning.
The research, conducted by investigators at NYU Langone Health and its Perlmutter Cancer Center, indicates that this treatment approach could significantly improve survival rates and lower the risk of cancer metastasis. The findings were shared at the 2026 American Society of Clinical Oncology meeting and published in the Journal of Clinical Oncology.
Cancer therapies have seen dramatic changes over recent years. Once, options were primarily limited to surgery, chemotherapy, and radiation. Today, immunotherapy has become a cornerstone treatment, leveraging the body’s own immune system to fight cancer more effectively.
While immunotherapy has revolutionized care for many melanoma patients, its effectiveness varies. Some tumors develop ways to evade immune detection and may return months or even years after initial treatment.
To address this challenge, researchers developed a personalized vaccine called intismeran. Unlike traditional vaccines designed to prevent certain infections, this vaccine is tailored for each patient.
Researchers analyze a patient’s tumor tissue after surgery to identify dozens of abnormal proteins known as neoantigens. These neoantigens act like unique fingerprints that differentiate cancer cells from healthy ones.
Using mRNA technology, scientists then create a custom vaccine that contains instructions targeting these specific tumor markers. When injected, the vaccine trains the immune system to recognize and attack cells displaying these markers. The objective is to bolster immune cells to eliminate any remaining melanoma cells before they can form new tumors.
This vaccine was tested alongside pembrolizumab, a widely used immunotherapy drug that works by blocking a protein called PD-1 — a protein cancer cells often exploit to hide from immune detection. By inhibiting PD-1, pembrolizumab helps restore the immune system’s ability to identify and attack cancer.
From 2019 to 2021, the clinical trial enrolled patients in the U.S. and Australia. All had previously undergone surgery to remove melanoma. Researchers compared the outcomes of patients who received both the personalized vaccine and pembrolizumab with those who received only pembrolizumab.
After five years, the results showed a clear advantage for the combination group. Nearly 70% remained cancer-free, while less than 50% of those treated with just pembrolizumab achieved the same. The combined approach cut the risk of recurrence or death by nearly half.
Additionally, patients receiving the combined therapy were less likely to experience the spread of melanoma to distant organs—an essential factor since metastatic melanoma is much harder to treat and accounts for many cancer-related deaths. Survival rates were also notably higher among recipients of the personalized vaccine.
These findings provide some of the strongest evidence to date that mRNA technology can be effectively used against cancer.
While mRNA gained widespread attention during the pandemic, its potential in oncology has been under investigation for years. One major advantage of mRNA is its adaptability—scientists can quickly design treatments tailored to the genetic makeup of an individual’s tumor.
This personalized approach is especially promising for cancers like melanoma, which often harbor numerous mutations. The more unique markers a tumor has, the more targets the immune system can be trained to recognize and attack.
The safety profile observed in the study was encouraging, with most side effects being manageable, including fatigue, chills, and injection site discomfort. No serious safety issues emerged during the trial.
Despite these positive results, experts emphasize that further research is necessary. Since this was a Phase IIb trial, larger studies are needed before the treatment can become a standard option. Fortunately, a Phase III international trial is already in progress, which will help confirm the vaccine’s effectiveness on a broader scale.
Scientifically, these results are highly significant. They suggest that personalized vaccines could enhance existing immunotherapy treatments rather than replace them. This combined strategy might serve as a model for future cancer therapies.
However, given the small size of this study, cautious interpretation is advised until larger trials are completed. If future research confirms these findings, personalized mRNA vaccines could represent a major breakthrough in cancer treatment—potentially applicable to many different types of cancer.
For those interested in skin health, studies have linked fish consumption with a higher risk of skin cancer, while Vitamin B3 may help prevent skin cancers. Additional research discusses how vegetable oils might contribute to cancer spread and how vitamin D could assist in treating skin inflammation.
Source: NYU Langone Health